In tumour cells lacking HR proficiency, PARG inhibition appears to cause synthetic lethality [22, 35–37], in a similar vein to the archetypal synthetic lethality of PARP inhibitors in BRCA1/2-deficient breast cancer cells [38, 39]. The gene discussed is PARP1; the disease is neoplasm.